Track topics on Twitter Track topics that are important to you
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson's.
Medscape Medical News
Original Article: Extended-Release Amantadine Effective for Dyskinesia in PDNEXT ARTICLE
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...